期刊文献+

骨肉瘤组织凋亡诱导因子与波形蛋白表达及其临床意义的探讨

Expression and clinical significance of AIF and VIM in human osteosarcoma tissues
原文传递
导出
摘要 目的:探讨凋亡诱导因子(AIF)与波形蛋白(VIM)在人骨肉瘤组织中的表达及对骨肉瘤的诊断和预后评估的价值。方法:采用免疫组化技术检测45例骨肉瘤、30例骨软骨瘤的AIF与VIM的表达。结果:AIF和VIM在骨肉瘤细胞中表达阳性率分别为66.70%(30/45)和73.81%(33/45),AIF与VIM在骨软骨瘤组织中低表达;AIF和VIM在骨肉瘤组织中表达无显著相关性,P>0.05;AIF与VIM的表达与性别、年龄、病程、肿瘤体积、分化程度以及生存状况均无关,P>0.05。AIF的表达与骨肉瘤瘤的转移无关,P>0.05,VIM的表达与骨肉瘤的转移相关,P<0.05。结论:AIF和VIM与骨肉瘤的发生密切相关,是评价骨肉瘤的重要指标。 OBJECTIVE: To study the association of apoptosis inducing factor (AIF) and vimentin (VIM) in osteo- sarcoma with diagosis, metastasis and prognosis. METHODS: Microwave SP-immunohistochemical method was used to detect 45 cases of osteosarcoma in the expression of AIF and VIM, combined with the biological behavior of osteosarcoma and clinical follow-up data for analysis and evaluation. At the same time with 30 cases of benign tumor of bone cartilage as a negative control. RESULTS: AIF in osteosarcoma and VIM expression rates were 66. 70% (30/45) and 73. 81% (33/45). AIF and VIM was weakly expressed in benign tumor of bone cartilage with no statistical significance between both group(P〉0.05). AIF and VIM expression in osteosarcoma was not related to sex, age, progress, differentiation, lymph node metastasis(P〉0.05). VIM was related to metastasis(P〈0.05), but AIF not(P〉0.05). CONCLUSION: Expression of AIF and VIF is related to, and main factors to evaluate detection of expression of AIF and VIM, and the prognosis of osteosarcoma.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2012年第5期347-350,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 凋亡诱导因子(AIF) 波形蛋白(VIM) 骨肉瘤 免疫组化 apoptosis inducing factor vimentin osteosarcoma immunohistochemistry
  • 相关文献

参考文献13

  • 1何忠惠,余文熙,林峰,郑水儿,汤丽娜,沈赞,姚阳.骨肉瘤组织CRM1基因表达预后意义的分析[J].中华肿瘤防治杂志,2009,16(12):930-933. 被引量:3
  • 2Fernandez-luna JL. Apoptosis regulators as targets for cancer thera- py[J]. Clin Transl Oncol,2007,5(9) :555-562.
  • 3Skyrlas A, Hantschke M, Passa V. Expression of apoptosis-in- dueing factor (AIF) in keratoacanthomas and squamous cell car- cinomas of the skin [J]. Exp Dermatol, 2011, 16 (10) : 1600- 1625.
  • 4Osborn M, Weber K. Intermediate filaments: cell-type-specific markeI in diferentiation and pathology[J]. Cell, 1982,31: 303- 306.
  • 5Miramar MD, Costantini P, Ravagnan L, et al. NADH-oxidaseac- tivity of mitochondrial apoptosis- inducing factor (AIF) [J]. J Biol Chem, 2001, 276(19):16381-16388.
  • 6Delavall6e L, Cabon L, Galdn-Malo P, et al. AIF-mediated caspase-independent necroptosis: A new chance for targeted therapeutics[J]. IUBMB Life, 2011,63(4) :221-232.
  • 7Susin SA, Lorenao HK, Zam zami N, et al. Molecular character ization of mitochondrial apoptosis- inducing factor[J]. Nature, 1999, 67(18) :441-446.
  • 8李海霞,鲁艳明,温冬雪,张淑兰.凋亡诱导因子在宫颈癌组织中的表达及意义[J].中国医科大学学报,2009,38(4):268-269. 被引量:5
  • 9徐浩翔,王宝玺.波形蛋白与疾病关系的研究进展[J].基础医学与临床,2009,29(10):1117-1120. 被引量:9
  • 10李普,秦超,殷长军,孟小鑫,杨健,朱建.肾癌组织中Vimentin蛋白表达与临床相关性分析[J].南京医科大学学报(自然科学版),2009,29(4):491-494. 被引量:3

二级参考文献35

  • 1张继强,秦达念,崔海燕.局部高温对青春期前大鼠睾丸支持细胞波形蛋白的影响及其与生精细胞凋亡的关系[J].中华男科学杂志,2006,12(3):202-206. 被引量:13
  • 2罗勇,贺大林,宁亮,朱国栋,申树林.前列腺癌细胞株LNCaP和IA8中转移相关蛋白的差异表达及意义[J].中华男科学杂志,2006,12(3):230-233. 被引量:4
  • 3张巍,张勇,孟艳玲,温伟红,薛茜,任君琳,杨安钢.人截短型凋亡诱导因子对HeLa细胞的促凋亡作用[J].第四军医大学学报,2007,28(7):577-580. 被引量:2
  • 4ZOU Jun,CHANG Tian-hui,CHANG He,Eishin Yaoita,Yutaka Yoshida,Masaaki Nameta,Tadashi Yamamoto,JIN Xin.Time course of expression of intermediate filament protein vimentin,nestin and desmin in rat renal glomerular injury[J].Chinese Medical Journal,2007(13):1203-1205. 被引量:6
  • 5Yang Yao, Hui Zhao, Yunjue Sun, et al. Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for hu man colorectal cancer[J].Tohoku J Exp Med,2008,215:267-278.
  • 6Meyers P, Schwartz C, Krailo M, et al. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate[J].J Clin Oncol,2005,23(9):2004-2011.
  • 7Lo H W, Seyed M A, Wu Y, et al. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin bl and CRM1 [J].J Cell Biochem, 2006,98 : 1570-1583.
  • 8Kager L, ZoubekA, Potschger U, et al. Primary metastaticos teosarcoma: presentation and outcome of patients treated on neo adjuvant cooperative osteosarcoma study group protocols[J].J Clin Oncol,2003,21(10):2011-2018.
  • 9Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presenta tion: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of metho trexate and ifosfamide[J]. Ann Oneol, 2003,14(7): 1126-1134.
  • 10Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome the French Pediatric Experience[J]. Cancer,2005,104(5) : 1100-1109.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部